1. Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma. Issue 20 (10th July 2021) Authors: Kumar, Anita; Casulo, Carla; Advani, Ranjana H.; Budde, Elizabeth; Barr, Paul M.; Batlevi, Connie L.; Caron, Philip; Constine, Louis S.; Dandapani, Savita V.; Drill, Esther; Drullinsky, Pamela; Friedberg, Jonathan W.; Grieve, Clare; Hamilton, Audrey; Hamlin, Paul A.; Hoppe, Richard T.; Horwitz, S... Journal: Journal of clinical oncology Issue: Volume 39:Issue 20(2021) Page Start: 2257 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA‐Ven) or liposomal daunorubicin‐cytarabine (CPX‐351). Issue 6 (8th April 2021) Authors: Salhotra, Amandeep; Aribi, Ahmed; Ngo, Dat; Zhang, Jianying; Sandhu, Karamjeet; Al‐Malki, Monzr; Ali, Haris; Koller, Paul; Arslan, Shukaib; Budde, Elizabeth; Khaled, Samer; Dadwal, Sanjeet; Snyder, David S.; Artz, Andrew; Forman, Stephen; Nakamura, Ryotaro; Stein, Anthony; Marcucci, Guido; Aldoss... Journal: American journal of hematology Issue: Volume 96:Issue 6(2021) Page Start: E196 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. The Bcl‐2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML. Issue 8 (8th January 2019) Authors: Nguyen, Le Xuan Truong; Troadec, Estelle; Kalvala, Arjun; Kumar, Bijender; Hoang, Dinh Hoa; Viola, Domenico; Zhang, Bin; Nguyen, Dang Quan; Aldoss, Ibrahim; Ghoda, Lucy; Budde, Elizabeth; Pichiorri, Flavia; Rosen, Steven; Forman, Stephen J.; Marcucci, Guido; Pullarkat, Vinod Journal: Journal of cellular physiology Issue: Volume 234:Issue 8(2019:Aug.) Page Start: 14040 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗